StockNews.AI
ICU
StockNews.AI
111 days

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

1. CEO Eric Schlorff will appear on Benzinga All Access Show today. 2. SeaStar's QUELIMMUNE for pediatric AKI was FDA approved in 2024. 3. SCD therapy has Breakthrough Device Designation for four indications. 4. A pivotal trial for SCD therapy in adults with AKI is ongoing. 5. Over 200,000 adults in the U.S. face AKI each year with no effective treatments.

4m saved
Insight
Article

FAQ

Why Bullish?

FDA approvals and pivotal trials suggest growing market potential. Past examples show stocks often rise post-approval news.

How important is it?

FDA approvals and trials are crucial indicators of future performance and investment interest.

Why Long Term?

The ongoing trial and product launches pave the way for sustainable company growth.

Related Companies

AXNXDHRMDT
April 30, 2025 08:05 ET  | Source: SeaStar Medical DENVER, April 30, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will be a featured guest today, Wednesday, April 30th, at approximately 10:50 am Eastern Time on the Benzinga All Access Show. The event will be broadcast live and can be viewed at https://youtube.com/live/ki1hFktn_2Y?feature=share. An archived recording of the presentation will be available on the investor relations section of the Sea Star Medical’s website on the Events and Presentations page. About SeaStar Medical SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for four therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually. For more information visit www.seastarmedical.com or visit us on LinkedIn or X. Contact:  IR@SEASTARMED.COM

Related News